Medical Bulletin 08/August/2026 - Video

Here are the top medical news for today:

New Double-Punch Strategy Shows Promise Against Aggressive Brain Cancer: Study

What if the same tiny particle could act like a surgeon's flashlight first—and a cancer killer next?

Scientists have developed an innovative nanoparticle platform that could help surgeons remove glioblastoma, the deadliest form of brain cancer, while also destroying microscopic cancer cells left behind after surgery. The research, published in Science Translational Medicine, was led by teams from the University of Technology Sydney (UTS), Harvard University, and Henan University.

Glioblastoma is notoriously difficult to treat because its cells spread deep into healthy brain tissue, making complete surgical removal almost impossible. The blood-brain barrier also blocks many drugs from reaching the tumour, contributing to a five-year survival rate of just around 7%.

The newly developed "double-punch" nanozyme tackles both challenges using a single smart material. Built from an ultrathin two-dimensional sheet embedded with individual platinum atoms, the platform performs two different tasks using the same near-infrared light.

During surgery, the nanoparticles act as an imaging guide. A specially designed fluorescent dye glows under near-infrared light, allowing surgeons to identify tumour cell clusters as small as 44 micrometres—far beyond the resolution of current clinical imaging. A targeting molecule also helps the material cross the blood-brain barrier and selectively accumulate inside glioblastoma cells.

After surgeons remove the visible tumour, the same material is applied to the surgical cavity and reactivated with near-infrared light. The platinum atoms convert the tumour's hydrogen peroxide into oxygen, helping overcome the low-oxygen environment that protects cancer cells. At the same time, the light generates heat and reactive molecules that destroy remaining microscopic cancer cells.

In mouse models, the approach completely prevented tumour recurrence during the study period, with 100% of treated mice surviving for 60 days, compared with 42 days for animals treated with surgery alone. Researchers reported no detectable neurological or movement problems.

The scientists caution that these findings are still limited to animal studies. Larger studies and human clinical trials will be needed to confirm whether this promising technology can safely improve glioblastoma surgery and reduce recurrence in patients.

REFERENCE: Ping Shangguan et al. ,Spatiotemporal-switchable 2D NIR-II single-atom nanozyme for single-cell–level surgical navigation and glioblastoma phototherapy.Sci. Transl. Med.18,eaeb8054(2026).DOI:10.1126/scitranslmed.aeb8054

Research Shows Depression May Reduce Brain Memory Centre Volume in Older Adults

What if depression quietly shrinks your brain's memory center—long before memory problems even begin?

Depression may leave a subtle mark on the aging brain years before dementia symptoms appear, according to a new study from the USC Mark and Mary Stevens Neuroimaging and Informatics Institute. Researchers found that older adults with depression had a smaller volume in a specific part of the hippocampus—a brain region essential for learning and memory—even though they had no signs of cognitive impairment.

Published in Translational Psychiatry, the study analyzed high-resolution brain scans from 2,009 cognitively healthy adults aged 50 to 90 years. Of these, 630 participants had depression based on current symptoms or a previous diagnosis.

Instead of examining the hippocampus as a single structure, researchers focused on three subregions. They found that depression was specifically linked to a smaller CA23DG region, which plays a crucial role in retrieving memories, distinguishing between similar experiences, and reconstructing memories from incomplete information. No significant differences were seen in the CA1 or subiculum regions.

Importantly, the association remained even after accounting for body mass index, physical activity, amyloid and tau proteins, and the APOE ε4 gene—well-known Alzheimer's disease risk factors. This suggests depression may affect brain structure through biological pathways that are at least partly separate from those linked to Alzheimer's disease.

The researchers also observed that participants with depression who reported taking antidepressants had smaller CA1 and CA23DG volumes than those not taking medication. However, they stressed this does not mean antidepressants caused the changes. People receiving medication may have experienced more severe or long-lasting depression, and the study could not separate medication effects from illness severity.

The findings do not prove that depression causes brain shrinkage or predicts Alzheimer's disease. Instead, they highlight a vulnerable memory-related brain region and reinforce the importance of recognizing and treating depression as part of healthy brain aging.

REFERENCE: Luu, D., Twisselmann, A.M., Tennant, V.R. et al. Depression and hippocampal subfield volume in older adults. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04223-y

New Study Suggests Just One Weekly Workout Could Help Reduce Belly Fat

Too busy to work out three times a week? One power-packed walk might be all your body needs.

A single 75-minute session of brisk interval walking each week may help reduce body fat and improve fitness almost as effectively as exercising three times weekly, according to a new study from the University of Hong Kong (HKUMed). The findings, published in Nature Communications, suggest that even people with packed schedules can gain meaningful health benefits with just one focused workout.

Researchers conducted a randomized trial involving 315 Chinese adults aged 18 years or older who were overweight and had central obesity—a condition marked by excess abdominal fat that raises the risk of heart disease, diabetes, and early death.

Participants were assigned to one of three groups: one completed 75 minutes of brisk interval walking once a week, another spread the same total exercise time across three weekly sessions, while a control group attended health education sessions every two weeks. The intervention lasted 16 weeks, with follow-up assessments four months later.

Body fat was measured using dual-energy X-ray absorptiometry (DXA) scans at the start, after 16 weeks, and again at 32 weeks.

The results showed that both exercise groups experienced similar reductions in total body fat, body fat percentage, and waist circumference. Participants in both groups also achieved comparable improvements in cardiorespiratory fitness when compared with the control group.

Interval walking alternates periods of brisk walking with slower recovery phases, making it a time-efficient form of exercise that has already been shown to reduce body and visceral fat.

Researchers say the findings could be especially valuable for adults who struggle to fit multiple workouts into busy schedules due to work, family, or other commitments.

Rather than insisting on frequent exercise sessions, a single weekly interval-walking workout may offer a realistic and effective alternative for managing central obesity.

REFERENCE: Parco M. Siu, et al.; Once and thrice weekly interval training in adults with central obesity: a randomized controlled trial. Nature Communications, 2026; 17 (1) DOI: 10.1038/s41467-025-68149-7